Luca Durelli
Luca Durelli
e-mail:
affiliation: Università di Torino
research area(s): Neuroscience
Course: Biomedical Sciences and Human Oncology
University/Istitution: Università di Torino
Professional Qualifications:

M.D. Degree, University of Torino Medical School, June 26th, 1974

Medical Licence, University of Torino Medical School, January 1975

Educational Commission for Foreign Medical Graduates (ECFMG) Examination, (January 22th, 1975)

Board of Neurology Certification, University of Torino Medical School, (July 11th, 1979)



State of Employment:

Director, Division of Neurology, University Hospital S.Luigi Gonzaga, Orbassano, Torino, Italy, from December 2003

Full Professor of Clinical Neurology, from March 29, 2007 to September 30, 2008 at the University of Torino Medical School and from October 1st to today at University of Torino Medical School San Luigi Gonzaga.

Associate Professor of Clinical Neurology, Clinic of Nervous System Diseases of Torino Medical School, from November 1, 1993 to March 18, 2007

Senior Researcher, Clinic of Nervous System Diseases, University of Torino Medical School, from August 1st 1980 to October 31st, 1993

Visiting Guest Worker, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland USA, from December 1st 1975 to January 31st 1977

Research Fellow and Clinic Resident , Clinic of Nervous and Mental Disease University of Torino Medical School, from November 1st 1974 to July 31 1980

Recipient of clinical Research Grants from Associazione Italiana Sclerosi Multipla (A.I.S.M.), Genova, Italia, from December 1991 to November 2001 (Titles: Effects of Interferon alpha-2a in RR MS; Effects of High Dose Methylprednisolone in Preventing Conversion to Definite MS; A Randomized comparison of Interferon beta-1b and Interferon beta-1a in RR MS).
Recipient of clinical Research Grants from Istituto Superiore di Sanita" (a branch of Italian Ministry of Health) from December 1997 to November 2001 (Titles: A Randomized comparison of Interferon beta-1b and Interferon beta-1a in RR MS; Myasthenia Gravis and Risk of Neoplastic Diseases)

Recipient of several grants from private companies, industries or foundations (either directly or through the Associazione F.I.R.N.I. Piemonte, ONLUS, of which Prof. Durelli is the President) both for the organization of Multicentre Studies in various fields of the treatment od neurological diseases as well as for sustaining the clinical and laboratory work of the Cetre for Autoimmune Diseases of the Dipartimento di Neuroscienze and then of the Dipartimento di Scienze Cliniche e Biologiche:

Merck-Serono, December 1998, Lire 80.000.000

Schering of Berlin from April 1999 to April 2003, in total Lire 2.825.000.000 + Euro 220.000

Specialized Therapeutics, Montville, NJ, USA, from September 2002 to Agosto 2004, in total USD 75.000 and Euro 220.000

Schering (or Bayer Schering or Bayer) Italia, from December 2004 to June 2008, in total Euro 350.000

Fondazione Cesare Serono, from April 2001 to May 2008, in total Lire 24.000.000 and Euro 107.000

Fondazione C.R.T. since 2008 to today, Euro 45.000

Publications:
Over 300 publications including 97 papers on Journals listed on Current Contents and 15 chapters on book (fields of interest: Clinical Neuroimmunology and treatment of autoimmune neurological diseases, mainly Multiple Sclerosis; Myasthenia Gravis; Autoimmune Polyneuropathy; Paraneoplastic Diseases)



Society Memberships:

Italian Society of EEG and Neurophysiology, from January 1st 1975
Italian Society of Neurology from October 1977
New York Academy of Sciences, from March 1986
American Academy of Neurology, from January 1987
International Society of Neuroimmunology from September 1987
Member of the Advisory Board of the Italian Society of Neurology, from November 1987 to October 1990
Member of the Scientific Advisory of Associazione Italiana Sclerosi Multipla (A.I.S.M.) since November 1993
President of F.I.R.N.I. Piemonte Onlus (Associazione Italiana per la Ricerca NeuroImmunologica in Piemonte) since 2001 to today.

Multiple Sclerosis; Miasthenia Gravis; Autoimmune Polineuropathies


1) INTERFERON-beta 1A FOR THE TRATMENT OF MULTIPLE SCLEROSIS
M.Clerico, G.Contessa, L.Durelli
Expert Opin. Biol. Ther. 2007;7: 535-542

2) ADHERENCE TO INTERFERON.BETA TREATMENT AND RESULTS OF THERAPY SWITCHING
M Clerico, P Barbero, G Contessa, C. Ferrero, L Durelli
J Neurol Sci 2007;259:104-108.

3) SUBGROUPS OF THE BENEFIT STUDY: RISK OF DEVELOPING MS AND
TREATMENT EFFECT OF INTERFERON BETA-1b.
Polman C, ... Durelli L, et al
J Neurol. 2008;255:480-7.


4) THE THERAPY OF MULTIPLE SCLEROSIS WITH IMMUNE-MODULATING OR IMMUNOSUPPRESSIVE DRUG A CRITICAL EVALUATION BASED UPON EVIDENCE BASED PARAMETERS AND PUBLISHED SYSTEMATIC REVIEWS.
Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.
Clin Neurol Neurosur 2008; 110: 878"885.


5) RECOMBINANT INTERFERON BETA OR GLATIRAMER ACETATE FOR DELAYING CONVERSION OF THE FIRST DEMYELINATING EVENT TO MULTIPLE SCLEROSIS
M.Clerico, F.Faggiano, J.Palace, G.Rice, M.Tintorè, L.Durelli
Cochrane Database Syst Rev. 2008;2: CD005278. Review.


6) MRI ACTIVITY AND NEUTRALIZING ANTIBODY AS PREDICTORS OF RESPONSE TO IFN-"ETA TREATMENT IN MS
L.Durelli, P.Barbero, M.Bergui, E.Versino, M.A.Bassano, E.Verdun, C.Rivoiro, C.Ferrero, E.Picco, P.Ripellino, G.Giuliani, E.Montanari, M..Clerico, for the Italian MS Study Group
J Neurol Neurosurg Psych 2008; 79:646-51


7) THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.
Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS
Study Group.
J Neurol. 2008; 255: 1315-23.


8) EPIDEMIOLOGY OF ALS IN ITALY: A 10-YEAR PROSPECTIVE POPULATION-BASED STUDY.
Chiò A, ... Durelli L, et al
Neurology. 2009;72:725-31.



9) COMORBIDITY BETWEEN CIDP AND DIABETES MELLITUS: ONLY A MATTER OF CHANCE?
Chiò A, ... Durelli L, et al
Eur J Neurol 2009;16:752-4.


10) COGNITIVE IMPAIRMENT AND ITS RELATION WITH DISEASE MEASURES IN MILDLY DISABLED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: BASELINE RESULTS FROM THE COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS (COGIMUS) STUDY.
Patti F, ... Durelli L, et al
Mult Scler 2009;15:779-88.


11) 250 MICROG OR 500 MICROG INTERFERON BETA-1B VERSUS 20 MG GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PROSPECTIVE, RANDOMISED, MULTICENTRE STUDY.
O'Connor P, ... Durelli L, et al
Lancet Neurol. 2009;8:889-97.



12) LONG-TERM EFFECT OF EARLY TREATMENT WITH INTERFERON BETA-1B AFTER A FIRST CLINICAL EVENT SUGGESTIVE OF MULTIPLE SCLEROSIS: 5-YEAR ACTIVE TREATMENT EXTENSION OF THE PHASE 3 BENEFIT TRIAL.
Kappos L, ... Durelli L, et al
Lancet Neurol. 2009;8:987-97.


13) THE PREVENTION OF POST-PARTUM RELAPSES WITH PROGESTIN AND ESTRADIOL IN MULTIPLE SCLEROSIS (POPART'MUS) TRIAL: RATIONALE, OBJECTIVES AND STATE OF ADVANCEMENT.
Vukusic S, ...Durelli L, et al
J Neurol Sci. 2009; 286: 114-8.


14) T HELPER 17 CELLS EXPAND IN MULTIPLE SCLEROSIS AND ARE INHIBITED BY INTERFERON-β
L Durelli, L Conti, M Clerico, D Boselli, G Contessa, P Ripellino, B Ferrero, P Eid,
F Novelli
Ann Neurol, 2009;65:499-509


15) NEUTRALIZING ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS
TREATED WITH 375 "CG INTERFERON-β-1b.
L Durelli, P Barbero, A Cucci, B Ferrero, A Ricci, G Contessa, S De Mercanti,
P Ripellino, D Lapuma, E Viglietta, M Bergui, E Versino & M Clerico; for the
OPTIMS Trial NAb Sub-Study Group
Expert Opin. Biol. Ther 2009; 9:387-397

16) EFFECTS OF IMMUNOMODULATORY TREATMENT WITH SUBCUTANEOUS INTERFERON BETA-1A ON COGNITIVE DECLINE IN MILDLY DISABLED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS.
Patti F, ... Durelli L, et al.
Mult Scler 2010; 16: 68-77.
No projects are available to students for the current accademic year.